L. McGrath

Abstract CT026: Evidence of immune activation in the first-in-human Phase Ia dose escalation study of the adenosine 2a receptor antagonist, AZD4635, in patients with advanced solid tumors

B. Linghu, C. Drake, J. Bendell, 2019, Clinical Trials.

Detecting T cell receptor rearrangements in silico from non-targeted DNA-sequencing (WGS/WES)

Tristan J. Lubinski, J. Barrett, H. Gardner, 2017, bioRxiv.

A phase I, open-label, multicenter study to assess the safety, pharmacokinetics, and preliminary antitumor activity of AZD4635 both as monotherapy and in combination in patients with advanced solid malignancies: Results from prostate cancer patients (NCT02740985).

B. Linghu, C. Drake, J. Bendell, 2020 .

Abstract CT011: NeoCOAST: open-label, randomized, phase 2, multidrug platform study of neoadjuvant durvalumab alone or combined with novel agents in patients (pts) with resectable, early-stage non-small-cell lung cancer (NSCLC)

J. Blando, J. Mazières, Y. Zheng, 2022, Cancer Research.

Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody

Changyun Hu, D. Wiederschain, M. Gostissa, 2022, Oncoimmunology.

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

G. Gibney, T. Seiwert, M. Callahan, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

929MO Platform study of neoadjuvant durvalumab (D) alone or combined with novel agents in patients (pts) with resectable, early-stage non-small cell lung cancer (NSCLC): Pharmacodynamic correlates and circulating tumor DNA (ctDNA) dynamics in the NeoCOAST study

J. Blando, O. Hamid, P. Forde, 2022, Annals of Oncology.

Abstract 4532: Preclinical evaluation of JTX-1811, an anti-CCR8 antibody with enhanced ADCC activity, for preferential depletion of tumor-infiltrating regulatory T cells

Changyun Hu, M. Gostissa, E. Stack, 2020, Immunology.

Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T Cell Activation in Tumors.

D. Wiederschain, Christina Meyer, M. Gostissa, 2023, Molecular cancer therapeutics.